Acronym NA
Category
Aquaculture
Marine Biotechnology
Title Development of recombinant oral vaccines using a bacterial carrier - Antigen expression in M. capsulatus
Programme National Programme
Instrument (FP6)
Contact Type (FP7)
Strand (Interreg)
NA
Theme (FP7)
Activity Area (FP6)
Regional Area (Interreg)
Action (COST)
NA
Specific Programme (FP7)
NA
Funding source National
Coordinator Johan R. Lillehaug
Coordinator email johan.lillehaug@mbi.uib.no
Coordinator institution
UiB - University of Bergen (Norway)
Institutions involved
NA
Start year 2004
End year 2010
Funding (€) € 463,700
Website https://prosjektbanken.forskningsradet.no/en/project/FORISS/162201?Kilde=FORISS&distribution=Ar&chart=bar&calcType=funding&Sprak=no&sortBy=date&sortOrder=desc&resultCount=30&offset=0&Fag.2=Basale+biofag&source=FORISS&projectId=165061
Summary We show that it is possible to express heterologous protein epitopes as parts of endogeneous surface proteins in M. capsulatus.M. cap. will be used as vehicle for antigen presentation and immunisation. We will characterise, using injection immunisation p rotocols in rabbit and fish, the immunogenic properties of M. cap. carrying various antigenes. Since M. cap. is approved for use in animal feed, immunization experiments including oral administration of M. cap. carrying the antigens will be performed to i nvestigate such constructs' activity as orally administered immunogens.Fish will be used as experimental model for the planned oral immunisation experiments.To optimise immunisation efficacy, we will study different outer membrane proteins of M. cap. to identify the optimal protein vehicle for presentation of heterologous antigens on its surface.A PCT application (PCT/NO02/00018) claiming the use of mopE as antigen carrier has been filed in Canada, EPO, Norway, and USA.This project is an offspring of the SUP grant no. 140785/420, 'GABI', which is the basis for the genome sequencing of M. cap. and the ongoing functional genomic/proteomic studies at UoB
Keywords
Bacteria;
Engineering;
Genetic;
Disease;
Vaccines development;
Marine Region
76
Not associated to marine areas
0
Marine Region Map